Therefore, we speculate that applying incretin-based medications in PD models can promote insulin secretion, improve peripheral and central insulin resistance, stabilize mitochondrial function, enhance energy metabolism, and exert neuroprotective effects that stabilize dopamine homeostasis (88). Here, INS is linked to Parkinson disease.